Want to see OCUL full AI Analyst Report?
Ocular Therapeutix (OCUL) Ratios
Ocular Therapeutix Ratios
OCUL's free cash flow for Q2 2026 was $-70.64M. For the 2026 fiscal year, OCUL's free cash flow was decreased by $-3.37M and operating cash flow was $-67.27M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 15.39 | 10.66 | 6.66 | 4.13 | 7.26 |
| Quick Ratio | 15.32 | 10.59 | 6.59 | 4.07 | 7.22 |
| Cash Ratio | 14.51 | 9.48 | 5.61 | 3.26 | 6.23 |
| Solvency Ratio | -1.70 | -1.33 | -0.48 | -0.61 | -0.04 |
| Operating Cash Flow Ratio | -4.03 | -3.26 | -2.01 | -1.90 | -2.49 |
| Short-Term Operating Cash Flow Coverage | -72.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 628.38M | $ 298.40M | $ 71.31M | $ 15.72M | $ 74.41M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.17 | 0.33 | 0.43 | 0.29 |
| Debt-to-Equity Ratio | 0.12 | 0.24 | 0.92 | 1.82 | 0.67 |
| Debt-to-Capital Ratio | 0.11 | 0.19 | 0.48 | 0.65 | 0.40 |
| Long-Term Debt-to-Capital Ratio | 0.10 | 0.18 | 0.45 | 0.60 | 0.37 |
| Financial Leverage Ratio | 1.23 | 1.45 | 2.77 | 4.22 | 2.33 |
| Debt Service Coverage Ratio | -17.05 | -12.97 | -5.86 | -8.82 | 0.38 |
| Interest Coverage Ratio | -22.82 | -12.65 | -7.27 | -11.20 | -11.70 |
| Debt to Market Cap | 0.03 | 0.05 | 0.21 | 0.25 | 0.10 |
| Interest Debt Per Share | 0.49 | 0.56 | 1.19 | 0.93 | 0.86 |
| Net Debt to EBITDA | 2.63 | 1.80 | 1.69 | 0.61 | -41.43 |
| Profitability Margins | |||||
| Gross Profit Margin | 87.31% | 91.17% | 90.96% | 91.18% | 89.88% |
| EBIT Margin | -490.33% | -282.36% | -118.74% | -124.32% | 0.27% |
| EBITDA Margin | -481.99% | -276.42% | -113.64% | -120.22% | 5.83% |
| Operating Profit Margin | -521.04% | -269.57% | -140.96% | -152.74% | -179.30% |
| Pretax Profit Margin | -513.17% | -303.67% | -138.14% | -137.95% | -15.06% |
| Net Profit Margin | -513.17% | -303.67% | -138.14% | -137.95% | -15.06% |
| Continuous Operations Profit Margin | -513.17% | -303.67% | -138.14% | -137.95% | -15.06% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 98.49% | 112.65% | 98.00% | 90.32% | 8.40% |
| Return on Assets (ROA) | -32.91% | -42.26% | -32.03% | -47.58% | -3.20% |
| Return on Equity (ROE) | -40.64% | -61.36% | -88.59% | -200.79% | -7.45% |
| Return on Capital Employed (ROCE) | -35.66% | -41.24% | -37.94% | -66.72% | -43.71% |
| Return on Invested Capital (ROIC) | -35.53% | -41.05% | -37.66% | -65.82% | -43.31% |
| Return on Tangible Assets | -32.91% | -42.26% | -32.03% | -47.58% | -3.20% |
| Earnings Yield | -11.70% | -14.32% | -22.68% | -32.89% | -1.23% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.69 | 1.97 | 2.23 | 2.41 | 2.06 |
| Payables Turnover | 1.58 | 1.35 | 1.20 | 0.89 | 0.96 |
| Inventory Turnover | 1.84 | 1.85 | 2.29 | 2.30 | 3.52 |
| Fixed Asset Turnover | 2.13 | 4.16 | 3.21 | 2.88 | 3.68 |
| Asset Turnover | 0.06 | 0.14 | 0.23 | 0.34 | 0.21 |
| Working Capital Turnover Ratio | 0.09 | 0.21 | 0.40 | 0.39 | 0.23 |
| Cash Conversion Cycle | 183.12 | 111.82 | 19.46 | -102.01 | -99.61 |
| Days of Sales Outstanding | 215.87 | 185.52 | 163.50 | 151.16 | 177.25 |
| Days of Inventory Outstanding | 197.88 | 197.23 | 159.31 | 158.70 | 103.55 |
| Days of Payables Outstanding | 230.64 | 270.93 | 303.35 | 411.87 | 380.41 |
| Operating Cycle | 413.75 | 382.74 | 322.81 | 309.86 | 280.80 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.09 | -0.85 | -0.88 | -0.78 | -0.86 |
| Free Cash Flow Per Share | -1.16 | -0.86 | -0.96 | -0.82 | -0.87 |
| Dividend Paid and CapEx Coverage Ratio | -17.06 | -104.56 | -11.54 | -16.04 | -54.90 |
| Capital Expenditure Coverage Ratio | -17.06 | -104.56 | -11.54 | -16.04 | -54.90 |
| Operating Cash Flow Coverage Ratio | -2.57 | -1.78 | -0.84 | -0.93 | -1.11 |
| Operating Cash Flow to Sales Ratio | -3.95 | -2.11 | -1.20 | -1.16 | -1.51 |
| Free Cash Flow Yield | -9.54% | -10.06% | -21.44% | -29.31% | -12.54% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.55 | -7.00 | -4.41 | -3.04 | -81.25 |
| Price-to-Sales (P/S) Ratio | 43.86 | 21.21 | 6.09 | 4.20 | 12.23 |
| Price-to-Book (P/B) Ratio | 3.47 | 4.29 | 3.91 | 6.11 | 6.05 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -10.48 | -9.94 | -4.66 | -3.41 | -7.98 |
| Price-to-Operating Cash Flow Ratio | -11.09 | -10.04 | -5.07 | -3.62 | -8.12 |
| Price-to-Earnings Growth (PEG) Ratio | -0.52 | -0.59 | -0.92 | 3.19 | 1.38 |
| Enterprise Value Multiple | -6.47 | -5.88 | -3.67 | -2.88 | 168.29 |
| Enterprise Value | 1.62B | 1.04B | 243.61M | 178.00M | 427.28M |
| EV to EBITDA | -6.47 | -5.88 | -3.67 | -2.88 | 168.29 |
| EV to Sales | 31.18 | 16.25 | 4.17 | 3.46 | 9.82 |
| EV to Free Cash Flow | -7.45 | -7.61 | -3.19 | -2.81 | -6.40 |
| EV to Operating Cash Flow | -7.89 | -7.69 | -3.47 | -2.99 | -6.52 |
| Tangible Book Value Per Share | 3.49 | 1.99 | 1.14 | 0.46 | 1.15 |
| Shareholders’ Equity Per Share | 3.49 | 1.99 | 1.14 | 0.46 | 1.15 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.28 | 0.40 | 0.73 | 0.67 | 0.57 |
| Net Income Per Share | -1.42 | -1.22 | -1.01 | -0.92 | -0.09 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.05 | 1.08 | 1.16 | 1.11 | -55.53 |
| Research & Development to Revenue | 3.80 | 2.00 | 1.04 | 1.04 | 1.15 |
| SG&A to Revenue | 2.28 | 1.60 | 0.58 | 1.32 | 0.73 |
| Stock-Based Compensation to Revenue | 0.83 | 0.52 | 0.30 | 0.33 | 0.34 |
| Income Quality | 0.77 | 0.70 | 0.87 | 0.84 | 10.00 |
Currency in USD
